Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

By Michael Gibney • Oct. 19, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023

PharmaVoice 100s: Cancer care visionaries

Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.

By Michael Gibney • Oct. 2, 2023

The PharmaVoice 100: Trailblazers

Leaders who are going where no biopharma executive has gone before and changing the industry along the way.

By Michael Gibney • Sept. 29, 2023

Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

By Michael Gibney • Sept. 28, 2023

PharmaVoice 100s: Standout execs

Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.

By Meagan Parrish • Sept. 25, 2023

For Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone

Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.

Sept. 25, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups

The biotech’s chief financial officer Robert Landry is retiring in February.

By Karissa Waddick • Sept. 12, 2023

Ex-Sanofi executive Sibold joins Madrigal as new CEO

Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.

By Ned Pagliarulo • Sept. 11, 2023

Pharma faces a slew of leadership shakeups

Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.

By Karissa Waddick • Sept. 7, 2023

‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

By Michael Gibney • Sept. 7, 2023

Roz Brewer announces sudden departure as CEO of Walgreens

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

By Meagan Parrish • Sept. 1, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

How an AstraZeneca exec is leading the charge in the next immuno-oncology era

The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

By Michael Gibney • Aug. 17, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

By Meagan Parrish • Aug. 11, 2023

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

By Michael Gibney • Aug. 8, 2023